首页> 美国卫生研究院文献>Clinical and Experimental Vaccine Research >In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate
【2h】

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate

机译:计算机分析基于包膜域III的多价融合蛋白作为潜在的登革热疫苗候选者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeDengue virus infection is now a global problem. Currently, there is no licensed vaccine or proven antiviral treatment against this virus. All four serotypes (1-4) of dengue virus can infect human. An effective dengue vaccine should be tetravalent to induce protective immune responses against all four serotypes. Most of dengue vaccine candidates are monovalent, or in the form of physically mixed multivalent formulations. Recently envelope protein domain III of virus is considered as a vaccine candidate, which plays critical roles in the most important viral activities. Development of a tetravalent protein subunit vaccine is very important for equal induction of immune system and prevention of unbalanced immunity. Here, we have presented and used a rational approach to design a tetravalent dengue vaccine candidate.
机译:目的登革热病毒感染现已成为全球性问题。当前,没有针对这种病毒的许可疫苗或经过验证的抗病毒治疗。登革热病毒的所有四种血清型(1-4)均可感染人类。有效的登革热疫苗应为四价疫苗,以诱导针对所有四种血清型的保护性免疫应答。大多数登革热疫苗候选物是单价的,或者是物理混合的多价制剂的形式。近来,病毒的包膜蛋白结构域III被认为是候选疫苗,它在最重要的病毒活性中起关键作用。四价蛋白质亚基疫苗的开发对于平等诱导免疫系统和防止免疫失衡非常重要。在这里,我们提出并使用了一种合理的方法来设计四价登革热疫苗候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号